Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is CSL Limited Sponsored (CSLLY - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
CSL Limited Sponsored is a member of our Medical group, which includes 905 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CSLLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CSLLY's full-year earnings has moved 3.37% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, CSLLY has returned 8.23% so far this year. At the same time, Medical stocks have gained an average of 2.22%. As we can see, CSL Limited Sponsored is performing better than its sector in the calendar year.
To break things down more, CSLLY belongs to the Medical - Biomedical and Genetics industry, a group that includes 387 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 0.32% so far this year, so CSLLY is performing better in this area.
Investors in the Medical sector will want to keep a close eye on CSLLY as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is CSL Limited Sponsored (CSLLY - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
CSL Limited Sponsored is a member of our Medical group, which includes 905 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CSLLY is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CSLLY's full-year earnings has moved 3.37% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, CSLLY has returned 8.23% so far this year. At the same time, Medical stocks have gained an average of 2.22%. As we can see, CSL Limited Sponsored is performing better than its sector in the calendar year.
To break things down more, CSLLY belongs to the Medical - Biomedical and Genetics industry, a group that includes 387 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 0.32% so far this year, so CSLLY is performing better in this area.
Investors in the Medical sector will want to keep a close eye on CSLLY as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CSLLY - FREE